{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-047920","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.221627+00:00","generated_at":"2026-05-17T00:50:40.814584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences Q3 net loss $21.8M ($1.84/sh); PBGENE-HBV doses Cohort 3, PBGENE-DMD IND on track","bullets":["Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.","Revenue <$0.1M, down from $0.6M YoY; R&D $13.4M, G&A $7.3M.","Cash $71.2M; expected runway into H2 2027 via cost cuts and potential near-term CAR T payments.","PBGENE-HBV Phase 1 dosing Cohort 3; late-breaking oral at AASLD on Nov 10.","PBGENE-DMD IND filing expected end-2025; Phase 1 start H1 2026, initial data H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-047920","json":"https://secwatch.observer/filing/0001628280-25-047920.json","markdown":"https://secwatch.observer/filing/0001628280-25-047920.md","text":"https://secwatch.observer/filing/0001628280-25-047920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/0001628280-25-047920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/dtil-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:50:40.814584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}